'Switch patients from osteoarthritis painkiller'

GPs must stop prescribing the painkiller lumiracoxib (Prexige) and switch patients to an alternative drug, says the Medicines and Healthcare products Regulatory Agency (MHRA).

Concerns over liver damage caused by the cyclooxygenase (COX)-2 inhibitor has led to suspension of the drug’s UK licence by the MHRA.

It follows similar moves by Australia, New Zealand, Turkey, the US and Canada earlier this year.

Data has shown that an increase in the number of serious liver reactions that have occurred with the licensed 100mg dose, some of which occurred within one month of use.

The drug was licensed for pain relief in osteoarthritis of the knee and hip and has been available in the UK since December 2005.

Between October 2006 and September 2007 alone, around 5,000 UK patients were given one or more scrips for the drug.

Up to 13 November, the MHRA received 23 reports of severe adverse reactions, three of which were liver reactions.

In August, the MHRA said the drug must be contraindicated in patients with a history of liver problems. But after closer examination of the evidence, the Committee on the Safety of Human Medicines, which is part of the MHRA, ruled that ‘previous measures could not be relied upon to guarantee patient safety’.

The latest finding adds to concerns about the side effects of COX-2 inhibitors after research linked them to an increased risk of cardiovascular event.

A spokeswoman for manufacturer Novartis advised GPs to make appointments for patients as soon as convenient to discuss switching to an alternative treatment.

‘Novartis continues to believe Prexige is an important treatment option,’ she added.

rachel.liddle@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

NHS Employers updates guidance for assessing COVID-19 risk in BAME staff

NHS Employers updates guidance for assessing COVID-19 risk in BAME staff

Updated guidance to help GP practices assess and mitigate the risk staff from black,...

PHE unable to confirm it will meet deadline for COVID-19 risk report

PHE unable to confirm it will meet deadline for COVID-19 risk report

Public Health England (PHE) has been unable to confirm if its report into how factors...

More than half of GP locums have seen a significant drop in income due to COVID-19

More than half of GP locums have seen a significant drop in income due to COVID-19

More than half of GP locums have experienced a significant fall in their income during...

How a GP helped develop a protective shield to cover patients needing CPR in the pandemic

How a GP helped develop a protective shield to cover patients needing CPR in the pandemic

Wiltshire GP Dr Lydia Campbell-Hill explains how she helped create a mini isolation...

GP practices can now sign up to new online PPE portal

GP practices can now sign up to new online PPE portal

GP practices will be able to register with the DHSC's new online PPE portal, which...

Fully-qualified GP workforce fell by 712 over the past year

Fully-qualified GP workforce fell by 712 over the past year

The fully-qualified GP workforce in England fell by 2.5%, losing 712 full-time equivalent...